
Myomo, Inc. (NYSE:MYO), a wearable medical robotics company that offers increased functionality for people with neurological disorders and upper-limb paralysis, announces the launch of the Myomo® Mobile App, a new

<p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Myomo, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/MYO">MYO</a>)</b>, a wearable medical robotics company that offers increased functionality for people with neurological disorders and upper-limb paralysis, announces the launch of the Myomo<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> Mobile App, a new digital tool designed to support clinicians and patients throughout the MyoPro<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> experience.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Myomo Mobile App is designed to make MyoPro care more intuitive, more connected, and more data-informed. For clinicians, the app provides a streamlined mobile interface for customizing EMG settings in person or remotely, including gain, threshold, range of motion, and advanced settings. It also gives clinicians visibility into patient usage and device configurations, helping support more proactive follow-up and care management.

</p><p xmlns="http://www.w3.org/1999/xhtml">
"For clinicians, the Myomo Mobile App is designed to simplify device configuration and improve visibility into patient use, whether care is delivered in clinic or remotely," said Paul R. Gudonis, Myomo's Chairman and Chief Executive Officer. "For patients, the app helps make muscle activity more understandable and encourages confidence through real-time feedback and easy access to training resources."

</p><p xmlns="http://www.w3.org/1999/xhtml">
For patients, the app provides real-time insight into muscle activity during everyday use, allowing users to view EMG signals and track repetitions at home or on the go. New visualizations are designed to mirror device movement and display the mode, helping patients better understand how the MyoPro responds to their muscle activity. The app also offers quick access to training materials and support resources to encourage independent self-management and continued progress.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Built on a modern digital infrastructure, the Myomo Mobile App is intended to support stronger data capture, expanded performance analytics, and support the development of future product capabilities. The app reflects the Company's broader commitment to improving the user experience for clinicians, caregivers, and patients across clinical and throughout patient's daily lives.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Myomo Mobile App is now available through the Google Play Store and Apple App Store and supporting user manuals for clinicians, patients, and caregivers are available on the company's website.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Myomo, Inc.</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.myomo.com&amp;esheet=54519063&amp;newsitemid=20260420253264&amp;lan=en-US&amp;anchor=www.myomo.com&amp;index=1&amp;md5=effaaae8beab0c78288d16d937fd951e" shape="rect">www.myomo.com</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements regarding the Company's future business expectations, including expectations regarding the benefits from and effectiveness of the Myomo Mobile App, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

</p><p xmlns="http://www.w3.org/1999/xhtml">
These factors include, among other things:

</p><ul xmlns="http://www.w3.org/1999/xhtml" class="bwlistdisc">
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to obtain sufficient reimbursement from third-party payers for our products;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our dependence on external sources for the financing of our operations;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to scale the business to achieve positive cash flow from operations;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our revenue concentration with patients who carry Medicare Part B;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to continue normal operations and patient interactions without supply chain disruption in order to deliver and fit our custom-fabricated devices;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our marketing and commercialization efforts;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to obtain and maintain our strategic collaborations and to realize the intended results of such collaborations;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our expectations as to our product development programs, including improving our existing products and developing new products;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our products;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our expectations as to our clinical research program and clinical results;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to gain and maintain regulatory approvals;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to compete and succeed in a highly competitive and evolving industry; and

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
general market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale of our products to patients.

</li>
</ul><p xmlns="http://www.w3.org/1999/xhtml">
More information about these and other factors that potentially could affect our financial results is included in Myomo's filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material or adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260420253264r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260420253264/en/" rel="nofollow">https://www.businesswire.com/news/home/20260420253264/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Media Contact: 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Sarah Stevenson
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:marketing@myomo.com" shape="rect">marketing@myomo.com</a>

</p>

Myomo Introduces Myomo Mobile App to Enhance Clinical Workflow and Patient Engagement

Myomo Mobile App Launch Aims to Enhance Patient and Clinician Engagement

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Myomo, Inc. (NYSE:MYO), a wearable medical robotics company that offers increased functionality for people with neurological disorders and upper-limb paralysis, announces the launch of the Myomo® Mobile App, a new</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Myomo has launched the Myomo Mobile App, designed to enhance engagement and support for clinicians and patients using the MyoPro device. This tool provides real-time data, improving the usability and understanding of muscle activity, potentially leading to increased device adoption and better patient outcomes.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Myomo launches Myomo Mobile App for enhanced patient care.</li><li>App provides clinicians with remote device management tools.</li><li>Patients gain real-time insights into muscle activity.</li><li>The app is available on Google Play and Apple App Store.</li><li>It supports future product capabilities and analytics.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Myomo, Inc. (MYO)</strong>: Myomo continues to innovate with its MyoPro product and digital tools, enhancing market positioning.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This development falls under Corporate Developments as it signifies a strategic enhancement in Myomo&#039;s offerings, reflecting the company&#039;s commitment to user experience and leveraging technology to improve patient care.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Increased visibility into patient usage may lead to better reimbursement outcomes.</li><li>The app&#039;s launch could drive higher adoption rates of MyoPro devices.</li><li>Real-time feedback may boost patient satisfaction and retention.</li><li>Stronger data analytics could enhance future product development.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Myomo Mobile App is available on major app stores.</li><li>The app enhances both clinician and patient experience with MyoPro.</li><li>Myomo focuses on addressing needs for neurological disorder patients.</li><li>MyoPro is currently the only marketed device in its category in the U.S.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider buying MYO for potential upside from enhanced app engagement and improved usage data within 6-12 months.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Myomo, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/MYO">MYO</a>)</b>, a wearable medical robotics company that offers increased functionality for people with neurological disorders and upper-limb paralysis, announces the launch of the Myomo<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> Mobile App, a new digital tool designed to support clinicians and patients throughout the MyoPro<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> experience.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Myomo Mobile App is designed to make MyoPro care more intuitive, more connected, and more data-informed. For clinicians, the app provides a streamlined mobile interface for customizing EMG settings in person or remotely, including gain, threshold, range of motion, and advanced settings. It also gives clinicians visibility into patient usage and device configurations, helping support more proactive follow-up and care management.

</p><p xmlns="http://www.w3.org/1999/xhtml">
"For clinicians, the Myomo Mobile App is designed to simplify device configuration and improve visibility into patient use, whether care is delivered in clinic or remotely," said Paul R. Gudonis, Myomo's Chairman and Chief Executive Officer. "For patients, the app helps make muscle activity more understandable and encourages confidence through real-time feedback and easy access to training resources."

</p><p xmlns="http://www.w3.org/1999/xhtml">
For patients, the app provides real-time insight into muscle activity during everyday use, allowing users to view EMG signals and track repetitions at home or on the go. New visualizations are designed to mirror device movement and display the mode, helping patients better understand how the MyoPro responds to their muscle activity. The app also offers quick access to training materials and support resources to encourage independent self-management and continued progress.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Built on a modern digital infrastructure, the Myomo Mobile App is intended to support stronger data capture, expanded performance analytics, and support the development of future product capabilities. The app reflects the Company's broader commitment to improving the user experience for clinicians, caregivers, and patients across clinical and throughout patient's daily lives.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Myomo Mobile App is now available through the Google Play Store and Apple App Store and supporting user manuals for clinicians, patients, and caregivers are available on the company's website.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Myomo, Inc.</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.myomo.com&amp;esheet=54519063&amp;newsitemid=20260420253264&amp;lan=en-US&amp;anchor=www.myomo.com&amp;index=1&amp;md5=effaaae8beab0c78288d16d937fd951e" shape="rect">www.myomo.com</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements regarding the Company's future business expectations, including expectations regarding the benefits from and effectiveness of the Myomo Mobile App, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

</p><p xmlns="http://www.w3.org/1999/xhtml">
These factors include, among other things:

</p><ul xmlns="http://www.w3.org/1999/xhtml" class="bwlistdisc">
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to obtain sufficient reimbursement from third-party payers for our products;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our dependence on external sources for the financing of our operations;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to scale the business to achieve positive cash flow from operations;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our revenue concentration with patients who carry Medicare Part B;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to continue normal operations and patient interactions without supply chain disruption in order to deliver and fit our custom-fabricated devices;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our marketing and commercialization efforts;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to obtain and maintain our strategic collaborations and to realize the intended results of such collaborations;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our expectations as to our product development programs, including improving our existing products and developing new products;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our products;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our expectations as to our clinical research program and clinical results;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to gain and maintain regulatory approvals;

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
our ability to compete and succeed in a highly competitive and evolving industry; and

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
general market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale of our products to patients.

</li>
</ul><p xmlns="http://www.w3.org/1999/xhtml">
More information about these and other factors that potentially could affect our financial results is included in Myomo's filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material or adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260420253264r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260420253264/en/" rel="nofollow">https://www.businesswire.com/news/home/20260420253264/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Media Contact: 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Sarah Stevenson
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:marketing@myomo.com" shape="rect">marketing@myomo.com</a>

</p>

Myomo has launched the Myomo Mobile App, designed to enhance engagement and support for clinicians and patients using the MyoPro device. This tool provides real-time data, improving the usability and understanding of muscle activity, potentially leading to increased device adoption and better patient outcomes.

Myomo Introduces Myomo Mobile App to Enhance Clinical Workflow and Patient Engagement

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News